Pathfinder International

Pathfinder International was originally incorporated as The Pathfinder Fund in 1957. Its family planning work began in the late 1920s when its founder Clarence Gamble, heir of the Procter & Gamble soap company fortune, supported efforts to introduce contraception to women and couples in the United States and 60 other countries. He also launched the first community-based service model, which is still the foundation of Pathfinder's operations.

Sarah Gamble, Clarence Gamble's wife, named the organization in honor of a quote by the poet Antonio Machado, "Traveler, there is no path, paths are made by walking."

Pathfinder surpassed revenue of US$100 million for the first time in the 2010 fiscal year.[2] In 2011, Pathfinder announced the retirement of Daniel E. Pellegrom, the longest-serving president of a global reproductive health organization in history after becoming CEO of Pathfinder International in 1985. In 2012, Purnima Mane joined Pathfinder as president and CEO, after serving as deputy director of United Nations Population Fund.[3]

Lois Quam, named three times to Fortune magazine's list of the most influential women leaders in business, became Pathfinder's President and CEO in 2017. She was chief operating officer of The Nature Conservancy and a senior advisor to Hillary Clinton's presidential campaign. She was selected by President Barack Obama to head his signature Global Health Initiative at the Department of State,[4] which provided more than $8 billion annually to help solve major health challenges facing millions of individuals across 80 countries.

Pathfinder was one of several nonprofits mentioned in Half the Sky: Turning Oppression into Opportunity for Women Worldwide, a best-selling book written by Nicholas Kristof and Sheryl WuDunn and first published in September 2009.

Pathfinder International works with many organizations, ranging from national ministries of health to local NGOs, to deliver reproductive health and family planning information and services to women, young adults and rural populations. Pathfinder's programs also integrate HIV/AIDS prevention and treatment activities. The group has worked with UN Women, the UNFPA, the World Bank and a number of other partners to organize different programs and projects.[5]

Pathfinder’s programs in more than 15 countries in Africa and South Asia expand access to modern contraception and comprehensive abortion care, and improve adolescent and youth sexual and reproductive health, fostering gender equality and resilience.[6]

A little over half of the group’s $130 million in funding came from the United States Agency for International Development in fiscal year 2019.[8] In addition, the organization receives funding from multilateral organizations, private foundations, and individuals. As part of the President's Emergency Plan for AIDS Relief, U.S. government support for AIDS prevention was contingent on opposing prostitution starting in 2003.[9] Pathfinder preferred to remain neutral so as not to alienate sex workers from its anti-HIV efforts, so it sued in federal court with other non-profit organizations.[10] In 2013, the U.S. Supreme Court found that the requirement violated the First Amendment's prohibition against compelled speech in Agency for International Development v. Alliance for Open Society International, Inc.[11] In early 2015, the U.S. Supreme Court returned with another ruling in favor of the Alliance for Open Society International. The latest decision affirmed a 2013 decision by the U.S. Supreme Court, which found that the government cannot tell its American grantees what they can and cannot say.[12]

Like many older birth control organizations, Pathfinder initially overlapped with the eugenics movement. The founder, Clarence Gamble, was a member of Human Betterment League of North Carolina and advocated forced sterilization of mental patients.[13]

During the 1970s, the organization was accused of distributing unsafe contraceptives. Specifically, Pathfinder continued to distribute the Dalkon Shield internationally after it had been withdrawn from the U.S. market due to high infection rates and used Depo-Provera when it was still considered experimental prior to FDA approval.[14]

• Non-Profit Report from GuideStar